We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+19.05%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.5B
AUM Growth
Cap. Flow
+$184M
Cap. Flow %
12.29%
Top 10 Hldgs %
43.16%
Holding
169
New
166
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.18%
2 Healthcare 10.75%
3 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VVUS
101
PUT
DELISTED
Vivus Inc
VVUS
$1.51M 0.1%
+120
New +$15.5K
AMRN
102
Amarin Corp
AMRN
$292M
$1.46M 0.1%
+12,564
New +$1.73M
ALNY icon
103
CALL
Alnylam Pharmaceuticals
ALNY
$32.7B
$1.45M 0.1%
+468
New +$12.5K
NBIX icon
104
PUT
Neurocrine Biosciences
NBIX
$15.6B
$1.41M 0.09%
+1,055
New +$13K
NS
105
PUT
DELISTED
NuStar Energy L.P.
NS
$1.38M 0.09%
+302
New +$14.9K
MRK icon
106
PUT
Merck
MRK
$352B
$1.36M 0.09%
+307
New +$13.7K
ORKA
107
Oruka Therapeutics
ORKA
$6.11B
$1.28M 0.09%
+654
New +$2M
ALBO
108
CALL
DELISTED
Albireo Pharma Inc
ALBO
$1.27M 0.08%
+101
New +$10.5K
VRTX icon
109
Vertex Pharmaceuticals
VRTX
$130B
$1.21M 0.08%
+15,108
New +$1.11M
CEMP
110
DELISTED
Cempra, Inc.
CEMP
$1.18M 0.08%
+150,000
New +$1.04M
AVNR
111
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.15M 0.08%
+250,000
New +$859K
RPRX
112
DELISTED
Repros Therapeutics Inc.
RPRX
$1.15M 0.08%
+62,090
New +$1.1M
MDGL icon
113
PUT
Madrigal Pharmaceuticals
MDGL
$12.1B
$1.09M 0.07%
+62
New +$16.2K
INFI
114
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.08M 0.07%
+666
New +$20.6K
MDGL icon
115
Madrigal Pharmaceuticals
MDGL
$12.1B
$1.08M 0.07%
+6,179
New +$1.61M
NS
116
DELISTED
NuStar Energy L.P.
NS
$1.08M 0.07%
+23,584
New +$1.16M
VIRX
117
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.04M 0.07%
+10
New +$11.1K
FRTX
118
CALL
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.03M 0.07%
+1
New +$11.1K
INCY icon
119
CALL
Incyte
INCY
$24.4B
$948K 0.06%
+431
New +$9.42K
ASTX
120
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$948K 0.06%
+2,307
New +$12.4K
TXMD icon
121
TherapeuticsMD
TXMD
$25M
$944K 0.06%
+6,232
New +$854K
VIRX
122
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$939K 0.06%
+859
New +$957K
LLY icon
123
Eli Lilly
LLY
$1.02T
$895K 0.06%
+18,222
New +$992K
ALXA
124
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$890K 0.06%
+2,050
New +$9.29K
UNXL
125
PUT
DELISTED
Uni-Pixel, Inc.
UNXL
$871K 0.06%
+592
New +$15.3K

Similar funds

Sabby Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Sabby Management, which disclosed 169 positions worth $1.5B. Its ten largest holdings account for 43% of the portfolio.

Its largest position is Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, followed by Healthcare and Energy.

  • Sabby Management's largest Q2 2013 buy was Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.
  • Sabby Management's ten largest holdings make up 43% of its $1.5B portfolio in Q2 2013.
  • Sabby Management disclosed 169 positions in Q2 2013, its first 13F filing on record.

Based on Sabby Management's 13F filing for Q2 2013, filed 14 Aug 2013.